Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronocort in Congenital Adrenal Hyperplasia
NCT03062280Phase 3Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Aug 2016
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydrocortisone in congenital adrenal hyperplasia (CAH), sponsored by Neurocrine Biosciences. Primary endpoints: Number of Participants With Adrenal Insufficiency, Number of Participants Who Used Sick Day Medication and 11 more. Started Aug 2016; status: completed.
02
Drugs
hydrocortisone
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT03062280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03062280.